# Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

> **NCT02192541** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Ziv-Aflibercept
- **DRUG:** Ganetespib

## Key facts

- **NCT ID:** NCT02192541
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12-02
- **Primary completion:** 2016-02-25
- **Final completion:** 2016-02-25
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Drug supplier suspended further clinical development of Ganetespib
- **Last updated:** 2018-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192541, "Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02192541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*